JP2009501746A5 - - Google Patents

Download PDF

Info

Publication number
JP2009501746A5
JP2009501746A5 JP2008521876A JP2008521876A JP2009501746A5 JP 2009501746 A5 JP2009501746 A5 JP 2009501746A5 JP 2008521876 A JP2008521876 A JP 2008521876A JP 2008521876 A JP2008521876 A JP 2008521876A JP 2009501746 A5 JP2009501746 A5 JP 2009501746A5
Authority
JP
Japan
Prior art keywords
amino
ethyl
purin
trans
imidazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008521876A
Other languages
Japanese (ja)
Other versions
JP5010599B2 (en
JP2009501746A (en
Filing date
Publication date
Priority claimed from GBGB0514809.3A external-priority patent/GB0514809D0/en
Application filed filed Critical
Publication of JP2009501746A publication Critical patent/JP2009501746A/en
Publication of JP2009501746A5 publication Critical patent/JP2009501746A5/ja
Application granted granted Critical
Publication of JP5010599B2 publication Critical patent/JP5010599B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (9)

式(I)：
Figure 2009501746
 [式中、
R1は、メチルまたはエチルを表し；
R2は、下記のリスト：
Figure 2009501746
 より選択される基を表し；
R3は、下記のリスト：
Figure 2009501746
 より選択される基を表し；
ここで、R4は、下記のリスト：
Figure 2009501746
 より選択される基を表し；
R5は、水素、C1-4アルキル、C1-4アルキルアリール、C1-4アルキルヘテロアリールまたはC1-4ヒドロキシアルキルを表し；
R6およびR7は独立して、水素、メチルまたはフェニルを表す]
の化合物、ならびにその塩および溶媒和物。 Formula (I):
Figure 2009501746
 [Where
R 1 represents methyl or ethyl;
R 2 has the following list:
Figure 2009501746
 Represents a group selected from;
R 3 lists below:
Figure 2009501746
 Represents a group selected from;
Where R 4 is the list below:
Figure 2009501746
 Represents a group selected from;
R 5 represents hydrogen, C 1-4 alkyl, C 1-4 alkylaryl, C 1-4 alkylheteroaryl or C 1-4 hydroxyalkyl;
R 6 and R 7 independently represent hydrogen, methyl or phenyl]
And their salts and solvates. R1がエチルを表す、請求項1に記載の化合物。 2. A compound according to claim 1, wherein R < 1 > represents ethyl. R2が基(i)、(ii)、(iii)または(iv)を表す、請求項1または請求項2に記載の化合物。 3. A compound according to claim 1 or claim 2, wherein R2 represents a group (i), (ii), (iii) or (iv). R5がHを表す、請求項1〜3のいずれか1項に記載の化合物。 R 5 represents H, compound according to any one of claims 1 to 3. R4が基(i)、(ii)、(iii)、(iv)または(v)を表す、請求項1〜4のいずれか1項に記載の化合物。 R 4 is a group (i), (ii), (iii), (iv) or (v) represents a compound according to any one of claims 1 to 4. (2R,3S,4R,5R)-2-(2-エチル-2H-テトラゾール-5-イル)-5-[2-{[2-(1H-イミダゾール-4-イル)エチル]アミノ}-6-({trans-4-[(2-{[2-(1H-イミダゾール-4-イル)エチル]アミノ}-1H-プリン-6-イル)アミノ]シクロヘキシル}アミノ)-9H-プリン-9-イル]テトラヒドロ-3,4-フランジオール；
(2R,3S,4R,5R)-2-(2-エチル-2H-テトラゾール-5-イル)-5-[2-{[2-(1-メチル-1H-イミダゾール-4-イル)エチル]アミノ}-6-({trans-4-[(2-{[2-(1-メチル-1H-イミダゾール-4-イル)エチル]アミノ}-1H-プリン-6-イル)アミノ]シクロヘキシル}アミノ)-9H-プリン-9-イル]テトラヒドロ-3,4-フランジオール；
(2R,3S,4R,5R)-2-(2-エチル-2H-テトラゾール-5-イル)-5-[2-{[2-(5-メチル-1H-イミダゾール-4-イル)エチル]アミノ}-6-({trans-4-[(2-{[2-(5-メチル-1H-イミダゾール-4-イル)エチル]アミノ}-1H-プリン-6-イル)アミノ]シクロヘキシル}アミノ)-9H-プリン-9-イル]テトラヒドロ-3,4-フランジオール；
(2R,3S,4R,5R)-2-(2-エチル-2H-テトラゾール-5-イル)-5-[2-{[4-(1-ピロリジニル)ブチル]アミノ}-6-({trans-4-[(2-{[4-(1-ピロリジニル)ブチル]アミノ}-1H-プリン-6-イル)アミノ]シクロヘキシル}アミノ)-9H-プリン-9-イル]テトラヒドロ-3,4-フランジオール；
(2R,3R,4S,5R)-2-(2-[(trans-4-アミノシクロヘキシル)アミノ]-6-{[trans-4-({2-[(trans-4-アミノシクロヘキシル)アミノ]-9H-プリン-6-イル}アミノ)シクロヘキシル]アミノ}-9H-プリン-9-イル)-5-(2-エチル-2H-テトラゾール-5-イル)テトラヒドロ-3,4-フランジオール；
(2R,3S,4R,5R)-2-(2-エチル-2H-テトラゾール-5-イル)-5-[2-{[2-(1H-イミダゾール-4-イル)エチル]アミノ}-6-({trans-4-[(2-{[2-(1H-イミダゾール-4-イル)エチル]アミノ}-4-ピリミジニル)アミノ]シクロヘキシル}アミノ)-9H-プリン-9-イル]テトラヒドロ-3,4-フランジオール；
(2R,3S,4R,5R)-2-(2-エチル-2H-テトラゾール-5-イル)-5-[2-{[2-(1-メチル-1H-イミダゾール-4-イル)エチル]アミノ}-6-({trans-4-[(2-{[2-(1-メチル-1H-イミダゾール-4-イル)エチル]アミノ}-4-ピリミジニル)アミノ]シクロヘキシル}アミノ)-9H-プリン-9-イル]テトラヒドロ-3,4-フランジオール；
(2R,3S,4R,5R)-2-(2-エチル-2H-テトラゾール-5-イル)-5-[2-{[2-(5-メチル-1H-イミダゾール-4-イル)エチル]アミノ}-6-({trans-4-[(2-{[2-(5-メチル-1H-イミダゾール-4-イル)エチル]アミノ}-4-ピリミジニル)アミノ]シクロヘキシル}アミノ)-9H-プリン-9-イル]テトラヒドロ-3,4-フランジオール；
(2R,3S,4R,5R)-2-(2-エチル-2H-テトラゾール-5-イル)-5-[2-{[4-(1-ピロリジニル)ブチル]アミノ}-6-({trans-4-[(2-{[4-(1-ピロリジニル)ブチル]アミノ}-4-ピリミジニル)アミノ]シクロヘキシル}アミノ)-9H-プリン-9-イル]テトラヒドロ-3,4-フランジオール；
(2R,3R,4S,5R)-2-(2-[(trans-4-アミノシクロヘキシル)アミノ]-6-{[trans-4-({2-[(trans-4-アミノシクロヘキシル)アミノ]-4-ピリミジニル}アミノ)シクロヘキシル]アミノ}-9H-プリン-9-イル)-5-(2-エチル-2H-テトラゾール-5-イル)テトラヒドロ-3,4-フランジオール；
である式(I)の化合物、またはそれらのいずれか1つの塩もしくは溶媒和物。 (2R, 3S, 4R, 5R) -2- (2-Ethyl-2H-tetrazol-5-yl) -5- [2-{[2- (1H-imidazol-4-yl) ethyl] amino} -6 -({trans-4-[(2-{[2- (1H-imidazol-4-yl) ethyl] amino} -1H-purin-6-yl) amino] cyclohexyl} amino) -9H-purine-9- Yl] tetrahydro-3,4-furandol;
(2R, 3S, 4R, 5R) -2- (2-Ethyl-2H-tetrazol-5-yl) -5- [2-{[2- (1-methyl-1H-imidazol-4-yl) ethyl] Amino} -6-({trans-4-[(2-{[2- (1-methyl-1H-imidazol-4-yl) ethyl] amino} -1H-purin-6-yl) amino] cyclohexyl} amino ) -9H-purin-9-yl] tetrahydro-3,4-furandol;
(2R, 3S, 4R, 5R) -2- (2-Ethyl-2H-tetrazol-5-yl) -5- [2-{[2- (5-methyl-1H-imidazol-4-yl) ethyl] Amino} -6-({trans-4-[(2-{[2- (5-methyl-1H-imidazol-4-yl) ethyl] amino} -1H-purin-6-yl) amino] cyclohexyl} amino ) -9H-purin-9-yl] tetrahydro-3,4-furandol;
(2R, 3S, 4R, 5R) -2- (2-Ethyl-2H-tetrazol-5-yl) -5- [2-{[4- (1-pyrrolidinyl) butyl] amino} -6-({trans -4-[(2-{[4- (1-pyrrolidinyl) butyl] amino} -1H-purin-6-yl) amino] cyclohexyl} amino) -9H-purin-9-yl] tetrahydro-3,4- Flange all;
(2R, 3R, 4S, 5R) -2- (2-[(trans-4-aminocyclohexyl) amino] -6-{[trans-4-({2-[(trans-4-aminocyclohexyl) amino] -9H-purin-6-yl} amino) cyclohexyl] amino} -9H-purin-9-yl) -5- (2-ethyl-2H-tetrazol-5-yl) tetrahydro-3,4-furandol;
(2R, 3S, 4R, 5R) -2- (2-Ethyl-2H-tetrazol-5-yl) -5- [2-{[2- (1H-imidazol-4-yl) ethyl] amino} -6 -({trans-4-[(2-{[2- (1H-imidazol-4-yl) ethyl] amino} -4-pyrimidinyl) amino] cyclohexyl} amino) -9H-purin-9-yl] tetrahydro- 3,4-flangeol;
(2R, 3S, 4R, 5R) -2- (2-Ethyl-2H-tetrazol-5-yl) -5- [2-{[2- (1-methyl-1H-imidazol-4-yl) ethyl] Amino} -6-({trans-4-[(2-{[2- (1-methyl-1H-imidazol-4-yl) ethyl] amino} -4-pyrimidinyl) amino] cyclohexyl} amino) -9H- Purin-9-yl] tetrahydro-3,4-furandol;
(2R, 3S, 4R, 5R) -2- (2-Ethyl-2H-tetrazol-5-yl) -5- [2-{[2- (5-methyl-1H-imidazol-4-yl) ethyl] Amino} -6-({trans-4-[(2-{[2- (5-methyl-1H-imidazol-4-yl) ethyl] amino} -4-pyrimidinyl) amino] cyclohexyl} amino) -9H- Purin-9-yl] tetrahydro-3,4-furandol;
(2R, 3S, 4R, 5R) -2- (2-Ethyl-2H-tetrazol-5-yl) -5- [2-{[4- (1-pyrrolidinyl) butyl] amino} -6-({trans -4-[(2-{[4- (1-pyrrolidinyl) butyl] amino} -4-pyrimidinyl) amino] cyclohexyl} amino) -9H-purin-9-yl] tetrahydro-3,4-furandol;
(2R, 3R, 4S, 5R) -2- (2-[(trans-4-aminocyclohexyl) amino] -6-{[trans-4-({2-[(trans-4-aminocyclohexyl) amino] -4-pyrimidinyl} amino) cyclohexyl] amino} -9H-purin-9-yl) -5- (2-ethyl-2H-tetrazol-5-yl) tetrahydro-3,4-furandol;
Or a salt or solvate of any one of them. 請求項1〜6のいずれか1項に記載の式(I)の化合物を含み、さらに1種以上の製薬上許容される希釈剤または担体を含む医薬組成物。   A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 6 and further comprising one or more pharmaceutically acceptable diluents or carriers. 医薬品として使用するための請求項1〜6のいずれか1項に記載の化合物。   7. A compound according to any one of claims 1 to 6 for use as a medicament. 炎症性疾患の治療のための医薬品の製造における請求項1〜6のいずれか1項に記載の化合物の使用。   Use of a compound according to any one of claims 1 to 6 in the manufacture of a medicament for the treatment of inflammatory diseases.
JP2008521876A 2005-07-19 2006-07-17 Purine derivatives that are agonists of adenosine A2A receptors Expired - Fee Related JP5010599B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0514809.3 2005-07-19
GBGB0514809.3A GB0514809D0 (en) 2005-07-19 2005-07-19 Compounds
PCT/EP2006/007078 WO2007009757A1 (en) 2005-07-19 2006-07-17 Purine derivatives as agonists of the adenosine a2a receptor

Publications (3)

Publication Number Publication Date
JP2009501746A JP2009501746A (en) 2009-01-22
JP2009501746A5 true JP2009501746A5 (en) 2009-08-27
JP5010599B2 JP5010599B2 (en) 2012-08-29

Family

ID=34897468

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008521876A Expired - Fee Related JP5010599B2 (en) 2005-07-19 2006-07-17 Purine derivatives that are agonists of adenosine A2A receptors

Country Status (9)

Country Link
US (1) US7985740B2 (en)
EP (1) EP1904512B1 (en)
JP (1) JP5010599B2 (en)
AR (1) AR054559A1 (en)
ES (1) ES2387404T3 (en)
GB (1) GB0514809D0 (en)
PE (1) PE20070179A1 (en)
TW (1) TW200740814A (en)
WO (1) WO2007009757A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214665B2 (en) * 2001-10-01 2007-05-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
EP1778712B1 (en) * 2004-08-02 2013-01-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
GT200500281A (en) * 2004-10-22 2006-04-24 Novartis Ag ORGANIC COMPOUNDS.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0523778D0 (en) * 2005-11-23 2006-01-04 Glaxo Group Ltd Novel method
US8178509B2 (en) * 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
PT2322525E (en) * 2006-04-21 2013-12-26 Novartis Ag Purine derivatives for use as adenosin a2a receptor agonists
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
WO2008000743A2 (en) * 2006-06-27 2008-01-03 Biovitrum Ab (Publ) Novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists
EP1889846A1 (en) * 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
CA2669108A1 (en) * 2006-11-10 2008-05-15 Novartis Ag Cyclopentene diol monoacetate derivatives
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
WO2009123881A1 (en) 2008-03-31 2009-10-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purine derivatives as a3 receptor- selective agonists
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists
JP5431476B2 (en) 2008-08-01 2014-03-05 アメリカ合衆国 A3 adenosine receptor antagonist and A3 adenosine receptor partial agonist

Family Cites Families (215)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3796700A (en) 1970-06-30 1974-03-12 Takedo Chem Ind Ltd Adenosine derivatives and the production thereof
US4224438A (en) 1970-07-14 1980-09-23 Boehringer Mannheim Gmbh Adenosine-5'-carboxylic acid amides
DE2034785A1 (en) 1970-07-14 1972-01-20 Boehnnger Mannheim GmbH, 6800 Mann heim Waldhof Adenosine 5 carboxylic acid derivatives
CA1019727A (en) 1971-03-18 1977-10-25 Abbott Laboratories Adenosine-5'-carboxylic acid amides
BE789773A (en) 1971-10-08 1973-04-06 Schering Ag ADENOSINES N6 -SUBSTITUTED AND THEIR PROCESS FOR
US3864483A (en) 1972-03-22 1975-02-04 Abbott Lab Adenosine-5{40 -carboxylic acid amides
CA1082695A (en) 1972-04-10 1980-07-29 Francis E. Fischer Process for preparing adenosine-5'-carboxamides
US3966917A (en) 1974-07-30 1976-06-29 Abbott Laboratories Platelet aggregation inhibitors
DE2621470A1 (en) 1976-05-14 1977-12-01 Pharma Waldhof Gmbh & Co Nucleoside carboxylic acid nitriles and derivs. - prepd. from a (5')-(O)-tosylated or halogenated nucleoside and a metal cyanide or alpha:alkali acetic acid
US4167565A (en) 1976-11-08 1979-09-11 Abbott Laboratories Adenosine-5'-carboxamides and method of use
AU8379182A (en) 1981-06-04 1982-12-09 Procter & Gamble Company, The Composition of salicylates and purine derivatives
CA1239397A (en) 1983-08-01 1988-07-19 James A. Bristol N.sup.6-substituted adenosines
DE3406533A1 (en) 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim USE OF ADENOSINE DERIVATIVES AS ANTIALLERGICA AND MEDICINAL PRODUCTS CONTAINING THEM
EP0305643B1 (en) 1984-04-18 1994-01-05 Whitby Research Incorporated N-6 thienyl substituted adenosine derivatives as cardiac vasodilators
US5310731A (en) 1984-06-28 1994-05-10 Whitby Research, Inc. N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents
US4663313A (en) 1984-10-26 1987-05-05 Warner-Lambert Company N6 -tricyclic adenosines for treating hypertension
CA1254888A (en) 1984-10-26 1989-05-30 Bharat Trivedi N.sup.6-bicycloadenosines
AU575438B2 (en) 1984-10-26 1988-07-28 Warner-Lambert Company N6 - substituted deoxyribose analogues of adenosines
US4738954A (en) 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US4755594A (en) 1986-01-31 1988-07-05 Warner-Lambert Company N6 -substituted adenosines
US5106837A (en) 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
US4757747A (en) 1986-04-08 1988-07-19 Vickers, Incorporated Power transmission
JPH0696534B2 (en) 1986-04-25 1994-11-30 ヘキストジヤパン株式会社 Anti-dementia agent
US4767747A (en) 1986-08-28 1988-08-30 Warner-Lambert Company Method for treating congestive heart failure with N6 -acenaphthyl adenosine
WO1988003148A2 (en) 1986-10-31 1988-05-05 Warner-Lambert Company Heteroaromatic derivatives of adenoside
WO1988003147A1 (en) 1986-10-31 1988-05-05 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
NL8702926A (en) 1986-12-15 1988-07-01 Sandoz Ag NEW FURANURONIC ACID DERIVATIVES AND METHODS FOR PREPARING AND USING THESE DERIVATIVES.
US4968697A (en) 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
PT86660B (en) 1987-02-04 1992-02-28 Ciba Geigy Ag PROCESS FOR THE PREPARATION OF ADENOSIN-5'-CARBOXAMIDE DERIVATIVES
US4962194A (en) 1987-04-02 1990-10-09 Warner-Lambert Company Method of preparing 51,N6-disubstituted adenosines from inosines
LU87181A1 (en) 1987-04-06 1988-11-17 Sandoz Sa NOVEL DERIVATIVES OF FURANNURONIC ACID, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
US5219840A (en) 1987-04-06 1993-06-15 Sandoz Ltd. Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
JPH0725785B2 (en) 1989-01-11 1995-03-22 日本臓器製薬株式会社 Adenosine derivative and pharmaceutical composition containing the compound as an active ingredient
DE3924424A1 (en) 1989-07-24 1991-01-31 Boehringer Mannheim Gmbh NUCLEOSIDE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICINAL PRODUCT AND THEIR USE IN THE SEQUENCING OF NUCLEIC ACID
US5646128A (en) 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
US5055569A (en) 1989-10-19 1991-10-08 G. D. Searle & Co. N-(6)-substituted adenosine compounds
PT95628A (en) 1989-10-19 1991-09-30 Searle & Co METHOD OF TREATMENT OF GASTROINTESTINAL MOBILITY DISTURBACTIONS WITH ADENOSIN COMPOUND
AU651569B2 (en) 1990-01-11 1994-07-28 Isis Pharmaceuticals, Inc. Compositions and methods for detecting and modulating RNA activity and gene expression
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5140015A (en) 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US5280015A (en) 1990-09-05 1994-01-18 The United States Of America As Represented By The Department Of Health And Human Services 2-substituted adenosines and 2-substituted adenosine 5'-carboxamides
ATE147074T1 (en) 1990-09-25 1997-01-15 Rhone Poulenc Rorer Int COMPOUNDS WHICH POSSESS ANTIHYPERTENSIVE AND ANTIISCHEMIC PROPERTIES
CA2100863A1 (en) 1991-01-23 1992-07-24 David A. Bullough Adenosine kinase inhibitors
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
FR2685918B1 (en) 1992-01-08 1995-06-23 Union Pharma Scient Appl NOVEL ADENOSINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2687678B1 (en) 1992-01-31 1995-03-31 Union Pharma Scient Appl NOVEL ADENOSINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US5552438A (en) 1992-04-02 1996-09-03 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
US5424297A (en) 1992-04-27 1995-06-13 University Of Virginia Alumni Patents Foundation Adenosine dextran conjugates
AU4772493A (en) 1992-07-15 1994-02-14 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Sulfo-derivatives of adenosine
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
IL108523A0 (en) 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
JPH08506343A (en) 1993-02-03 1996-07-09 ジェンシア・インコーポレイテッド Adenosine kinase inhibitors containing lysofuranosyl derivatives
EP0708781B1 (en) 1993-07-13 2001-10-04 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services A 3 adenosine receptor agonists
US5446046A (en) 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
WO1995018817A1 (en) 1994-01-07 1995-07-13 Laboratoires Upsa Novel adenosine derivatives, preparation methods therefor, and pharmaceutical compositions containing same
JP2989010B2 (en) 1994-06-15 1999-12-13 ザ、ウェルカム、ファンデーション、リミテッド Enzyme inhibitors
GB9414208D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
GB9414193D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
JPH11505702A (en) 1995-05-18 1999-05-25 コールター インターナショナル コーポレイション Assay reagents and methods of making and using the assay reagents
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US5789589A (en) 1996-04-22 1998-08-04 Drug Innovation & Design, Inc. Guanine analog phosphates
WO1998001459A1 (en) 1996-07-05 1998-01-15 Novo Nordisk A/S Novel n-alkoxyadenine derivatives acting as cytokine inhibitors
UA51716C2 (en) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. combinations possessing hypotensive, cardioprotective, anti-ishemic, and antilipolytic agents, a pharmaceutical composition and METHOD OF TREATMENT
AU4377397A (en) 1996-10-14 1998-05-11 Novo Nordisk A/S Novel therapeutically active adenosine derivatives
FR2757518B1 (en) 1996-12-23 1999-06-11 Hoechst Marion Roussel Inc NOVEL ERYTHROMYCIN DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
US6710051B1 (en) 1997-01-06 2004-03-23 Klaus Trier Aps Screening method
MY117948A (en) 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
DE19723722A1 (en) 1997-05-30 1998-12-10 Schering Ag Nonsteroidal progestogens
AU9281298A (en) 1997-10-01 1999-04-23 Kyowa Hakko Kogyo Co. Ltd. Benzodioxole derivatives
YU44900A (en) * 1998-01-31 2003-01-31 Glaxo Group Limited 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
CO4990969A1 (en) 1998-02-14 2000-12-26 Glaxo Group Ltd DERIVATIVES OF 2- (PURIN-9-IL) -TETRAHYDROFURAN-3,4-DIOL
EP1070056B1 (en) 1998-03-14 2004-06-30 ALTANA Pharma AG Phthalazinone pde iii/iv inhibitors
GB9811599D0 (en) 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
SK19542000A3 (en) * 1998-06-23 2001-09-11 Glaxo Group Limited 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives, process for producing thereof, pharmaceutical composition them containing, their use and intermediates
GB9813565D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813540D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US7214665B2 (en) 2001-10-01 2007-05-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
AR028986A1 (en) 1999-02-23 2003-06-04 Smithkline Beecham Corp USE OF A PDE4 INHIBITOR IN THE MANUFACTURE OF A CONTROLLED LIBERATION PREPARATION; FORMULATION OF CONTROLLED RELEASE FOR THE TREATMENT OF COPD, A PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION
WO2000066590A2 (en) 1999-05-04 2000-11-09 Ligand Pharmaceuticals, Inc. Tetracyclic progesterone receptor modulator compounds and methods
AU778450B2 (en) 1999-07-02 2004-12-09 Eisai R&D Management Co., Ltd. Fused imidazole compounds and remedies for diabetes mellitus
ES2165768B1 (en) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
US6263209B1 (en) 1999-07-28 2001-07-17 Motorola, Inc. Method and apparatus in a wireless communication system for creating a learning function
CO5180649A1 (en) 1999-09-01 2002-07-30 Abbott Lab ANTAGONISTS OF GLUCOCORTICOID RECEPTORS FOR THE TREATMENT OF DIABETES FOR THE TREATMENT OF DIABETES
US6803457B1 (en) 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
CZ20022413A3 (en) 2000-01-31 2003-08-13 Pfizer Products Inc. Pyrimidine carboxamides useful as inhibitors of PDE4 isozymes
MXPA02007419A (en) 2000-01-31 2002-12-09 Pfizer Prod Inc Nicotinamide benzofused heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes.
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US6710086B1 (en) 2000-02-25 2004-03-23 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor
US6753322B2 (en) 2000-06-06 2004-06-22 Pfizer Inc 2-aminocarbonyl-9H-purine derivatives
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
GB0015727D0 (en) 2000-06-27 2000-08-16 Pfizer Ltd Purine derivatives
GB0016002D0 (en) 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
KR20030031198A (en) 2000-09-29 2003-04-18 글락소 그룹 리미티드 Morpholin-acetamide derivatives for the treatment of inflammatory diseases
AU2002210761A1 (en) 2000-11-03 2002-05-15 Glaxo Group Limited Method of determining susceptibility to diseases
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
GB0031179D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Nitric oxide synthase inhibitors
DE10064997A1 (en) 2000-12-23 2002-06-27 Merck Patent Gmbh New 1-benzoyl-3-phenyl-tetrahydropyridazine derivatives, useful for treating e.g. allergy, are selective inhibitors of phosphodiesterase IV, and new intermediates
US6484903B2 (en) 2001-01-09 2002-11-26 Riverwood International Corporation Carton with an improved dispensing feature in combination with a unique handle
ATE292973T1 (en) 2001-01-16 2005-04-15 Can Fite Biopharma Ltd USE OF AN ADENOSINE A3 RECEPTOR AGONIST TO INHIBIT VIRUS REPLICATION
US7250518B2 (en) 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
EP1229034B1 (en) 2001-01-31 2005-04-13 Pfizer Products Inc. Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
GB0104555D0 (en) 2001-02-23 2001-04-11 Glaxo Group Ltd New Therapeutic method
GB2372742A (en) 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
US7144908B2 (en) 2001-03-08 2006-12-05 Glaxo Group Limited Agonists of beta-adrenoceptors
AU2002238748A1 (en) 2001-03-12 2002-09-24 Glaxo Group Limited Pharmaceutical aerosol formulation
ATE381537T1 (en) 2001-03-22 2008-01-15 Glaxo Group Ltd FORMANILIDE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS
YU71403A (en) 2001-03-30 2006-05-25 Pfizer Products Inc. Pyridazinone aldose reductase inhibitors
US20040204481A1 (en) 2001-04-12 2004-10-14 Pnina Fishman Activation of natural killer cells by adenosine A3 receptor agonists
US6903109B2 (en) 2001-04-18 2005-06-07 Ortho-Muniel Pharmaceutical, Inc. Arylindenopyridines and related therapeutic and prophylactic methods
GB0120124D0 (en) 2001-05-04 2001-10-10 Aventis Pharm Prod Inc Effect of timing and duration of administration of amp 579 on reperfusion injury in rabbit heart
US20030013675A1 (en) 2001-05-25 2003-01-16 Boehringer Ingelheim Pharma Kg Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
CA2448086A1 (en) 2001-05-25 2002-12-05 Pfizer Limited An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases
US20030078232A1 (en) 2001-08-08 2003-04-24 Elfatih Elzein Adenosine receptor A3 agonists
US7262176B2 (en) 2001-08-08 2007-08-28 Cv Therapeutics, Inc. Adenosine A3 receptor agonists
PL393155A1 (en) 2001-09-14 2011-03-28 Glaxo Group Limited Phenethanolamine derivatives for treating of respiratory diseases
SK1862004A3 (en) 2001-10-31 2004-08-03 Type 4 phosphodiesterase inhibitors and uses thereof
RU2004116686A (en) 2001-11-02 2005-03-27 Авентис Фармасьютикалз Инк. (Us) PHARMACEUTICAL COMPOSITION, INCLUDING A1 / A2-Adenosine Receptor Agonist and Sodium-Hydrogen Ion Exchange Inhibitor
CA2465746C (en) 2001-11-05 2011-09-06 Merck Patent Gesellschaft Mit Beschraenkter Haftung Hydrazono-malonitriles
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
US6911453B2 (en) 2001-12-05 2005-06-28 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them
GB0129273D0 (en) 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
US6703405B2 (en) 2001-12-22 2004-03-09 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as a medicament, and medicament containing them
DE10163991A1 (en) 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine
CA2472746A1 (en) 2002-01-14 2003-07-24 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof
WO2003062256A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
JP4745609B2 (en) 2002-01-22 2011-08-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Non-steroidal ligands for glucocorticoid receptors, compositions thereof and uses
CA2474337A1 (en) 2002-01-25 2003-07-31 Muscagen Limited Compounds useful as a3 adenosine receptor agonists
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
US6756392B2 (en) 2002-02-11 2004-06-29 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
JP4583761B2 (en) 2002-02-11 2010-11-17 ファイザー・インク Nicotinamide derivatives useful as PDE4 inhibitors
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
CA2479126C (en) 2002-03-18 2011-11-15 Schering Corporation Combination treatments for chemokine-mediated diseases
EP1486204A1 (en) 2002-03-18 2004-12-15 Yamanouchi Pharmaceutical Co. Ltd. Powdery medicinal compositions for inhalation and process for producing the same
GB0206657D0 (en) 2002-03-21 2002-05-01 Glaxo Group Ltd Novel intermediate and process
GB0206655D0 (en) * 2002-03-21 2002-05-01 Glaxo Group Ltd Novel process
ES2298508T3 (en) 2002-03-26 2008-05-16 Boehringer Ingelheim Pharmaceuticals Inc. GLUCOCORTICOID MIMETICS, METHODS TO PREPARE THEM, PHARMACEUTICAL COMPOSITIONS AND THEIR USES.
WO2003082787A1 (en) 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10215316C1 (en) 2002-04-02 2003-12-18 Schering Ag Quinoline and isoquinoline derivatives, a pharmaceutical agent and their use as anti-inflammatory agents
DE60335869D1 (en) 2002-04-11 2011-03-10 Merck Sharp & Dohme 1H-BENZO (F) INDAZOL-5-YL DERIVATIVES AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS
GB0208608D0 (en) 2002-04-13 2002-05-22 Glaxo Group Ltd Composition
US20040127510A1 (en) 2002-04-16 2004-07-01 Heintzelman Geoffrey R. Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
ES2298511T3 (en) 2002-04-25 2008-05-16 Glaxo Group Limited DERIVATIVES OF PHENETHANOLAMINE.
WO2003099290A1 (en) 2002-05-21 2003-12-04 Glaxo Group Limited Pharmaceutical products and methods of manufacture
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
PT1521733E (en) 2002-07-08 2014-10-29 Pfizer Prod Inc Modulators of the glucocorticoid receptor
WO2004009017A2 (en) 2002-07-18 2004-01-29 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US7442554B2 (en) 2002-07-18 2008-10-28 Bristol-Myers Squibb Company Compositions and methods involving glucocorticoid receptor site II
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
EP1532113B1 (en) 2002-08-21 2008-08-06 Boehringer Ingelheim Pharmaceuticals Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
AU2003265867A1 (en) 2002-08-29 2004-10-18 Oxford Glycosciences (Uk) Ltd. A3 receptor-mediated cardioprotective proteins and therapeutic and diagnostic methods of use
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
DE60330250D1 (en) 2002-09-09 2010-01-07 Cv Therapeutics Inc ADENOSINE A3 RECEPTOR AGONISTS
US20050288253A1 (en) 2002-09-09 2005-12-29 Trigen Limited Boronic acid salts
KR20050057294A (en) 2002-09-09 2005-06-16 트라이젠 리미티드 Boronic acid salts and their use in the treatment of thrombosis
PL375993A1 (en) 2002-09-16 2005-12-12 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
JP4516844B2 (en) 2002-09-16 2010-08-04 エイジェニックス インコーポレイテッド Lactoferrin in wound treatment
WO2004026248A2 (en) 2002-09-20 2004-04-01 Merck & Co., Inc. Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
US20040229780A1 (en) 2002-09-20 2004-11-18 Olivera Baldomero M. KappaM-conopeptides as organ protectants
AU2003270752A1 (en) 2002-09-27 2004-04-19 King Pharmaceuticals Research And Development, Inc. A method to demonstrate the efficacy of pharmacological stress agent
WO2004030621A2 (en) 2002-09-30 2004-04-15 The Trustees Of Boston University Method of treating cancer using adenosine and its analogs
ATE422203T1 (en) 2002-10-09 2009-02-15 Schering Corp THIADIAZOLE DIOXIDE AND THIADIAZOLOXIDE AS CXC AND CC CHEMOKINE RECEPTOR LIGANDS
KR20050047552A (en) 2002-10-11 2005-05-20 화이자 인코포레이티드 Indole derivatives as beta-2 agonists
US6844362B2 (en) 2002-10-11 2005-01-18 Pfizer Inc Indole derivatives useful for the treatment of diseases
EP1407769A1 (en) 2002-10-11 2004-04-14 Pfizer Limited Indole derivatives as beta-2 agonists
US20060205790A1 (en) 2002-10-22 2006-09-14 Coe Diane M Medicinal arylethanolamine compounds
US7199127B2 (en) 2002-10-25 2007-04-03 United States Of America, Represented By The Secretary, Department Of Health And Human Services Purine nucleosides
PL377122A1 (en) 2002-10-28 2006-01-23 Glaxo Group Limited Phenethanolamine derivative for the treatment of respiratory diseases
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
JP2006510634A (en) 2002-12-03 2006-03-30 ヴェラ ファーマスーティカルズ インコーポレイテッド Pharmaceutical composition of 1- (3,4-dimethoxyphenyl) -4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine and use thereof
GB0228723D0 (en) 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
PL378247A1 (en) 2003-01-14 2006-03-20 Altana Pharma Ag Pde4 inhibitors for the treatment of neoplasms of lymphoid cells
US20040166574A1 (en) 2003-02-25 2004-08-26 Antonius John I. Microorganism
US20040175382A1 (en) 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
GB0305153D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Identification of therapeutic compounds
GB0305149D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Compounds for the treatment of pain
GB0305150D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Use of therapeutic compounds
EP1460064A1 (en) 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide derivatives useful as beta-2 agonists
US20040184995A1 (en) 2003-03-17 2004-09-23 Yamanouchi Pharmaceutical Co., Ltd. Novel dry powder inhalation for lung-delivery and manufacturing method thereof
US20040258740A1 (en) 2003-04-10 2004-12-23 Nene Labs Transdermal delivery composition
BRPI0409492A (en) 2003-04-18 2006-05-02 Pharmacia & Up John Company Ll combination therapies
EP1477167A1 (en) 2003-05-15 2004-11-17 Pfizer Limited [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists
US7268147B2 (en) 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
US7067541B2 (en) 2003-06-04 2006-06-27 Pfizer Inc 2-amino-pyridine derivatives useful for the treatment of diseases
GB0312832D0 (en) 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
MXPA05013059A (en) 2003-06-04 2006-03-02 Pfizer 2-amino-pyridine derivatives as beta-2 adrenoreceptor agonists.
US7375100B2 (en) 2003-06-04 2008-05-20 Pfizer Inc 2-amino-pyridine derivatives useful for the treatment of diseases
WO2004110454A1 (en) 2003-06-13 2004-12-23 Ishihara Sangyo Kaisha, Ltd. COMPOSITION FOR TREATMENT FOR OR PREVENTION OF DISEASE NECESSITATING ADMINISTRATION OF ADENOSINE A2a RECEPTOR AGONIST
US6974862B2 (en) 2003-06-20 2005-12-13 Kensey Nash Corporation High density fibrous polymers suitable for implant
GB0317498D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Compounds
US7153870B2 (en) 2003-07-25 2006-12-26 Pfizer Inc. Nicotinamide derivatives useful as PDE4 inhibitors
GB0317484D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
US7132435B2 (en) 2003-07-25 2006-11-07 Pfizer Inc. Compounds
GB0317509D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
GB0317471D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Novel compounds
US20050020587A1 (en) 2003-07-25 2005-01-27 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
GB0317482D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
GB0317472D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
GB0317516D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
GB0317951D0 (en) 2003-07-31 2003-09-03 Trigen Ltd Compounds
NZ545979A (en) 2003-09-18 2009-02-28 King Pharmaceuticals Res & Dev Novel adenosine A3 receptor agonists
AR049384A1 (en) * 2004-05-24 2006-07-26 Glaxo Group Ltd PURINA DERIVATIVES

Similar Documents

Publication Publication Date Title
JP2009501746A5 (en)
JP6263533B2 (en) Dihydropyrimidine compounds and their application in medicine
US20210221793A1 (en) Pyrazole derivatives as sgc stimulators
RU2331642C2 (en) New kinase inhibitors
JP2019077725A5 (en)
JP2004517855A5 (en)
LU92602I2 (en) Trametinib, optionally in the form of a pharmaceutically acceptable salt, hydrate or solvate thereof
CN105008350B (en) Antiviral compound
JP2019507774A (en) Elimination of hepatitis B virus by antiviral agents
JP2016515545A (en) HCV RNA-polymerase NS5B nucleoside inhibitor, 2-{[(2R, 3S, 5R) -5- (4-amino-2-oxo-2H-pyrimidin-1-yl) -3-hydroxy-tetrahydro-furan -2-ylmethoxy] -phenoxy-phosphorylamino} -alkyl propionate, process for its preparation and use
JP2008543781A5 (en)
RU2005131165A (en) IMIDAZOLE-4-YLETINYLPYRIDINE DERIVATIVES
RU2008145704A (en) PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS
RU2007101236A (en) NEW HYDANTOINE DERIVATIVES FOR TREATMENT OF OBSTRUCTIVE RESPIRATORY DISEASES
PE20110063A1 (en) DERIVATIVES OF [1, 2, 4] TRIAZOLO [1, 5-a] PYRIDINE AS JAK INHIBITORS
PE20070179A1 (en) PURINE DERIVATIVES AS AGONISTS OF THE ADENOSINE A2 RECEPTOR
JP2006077019A5 (en)
JP2008523041A5 (en)
JP2010529147A5 (en)
NO20084853L (en) Compounds that are agonists of muscarinic receptors and which may be effective in the treatment of pain, Alzheimer&#39;s disease and / or schizophrenia
PE20060602A1 (en) HETEROARYL ACIL PYRROLIDINE DERIVATIVES AS INHIBITORS OF HEPATITIS C VIRUS (HCV)
JP2009525340A5 (en)
RU2013104038A (en) SELECTIVE WITH RESPECT TO PI3K p110 DELTA PURINE COMPOUNDS AND WAYS OF THEIR APPLICATION
RU2012139828A (en) Pyrazolopyiperidine derivatives as Nadph Oxidase Inhibitors
RU2354655C2 (en) Comt inhibitors